Oscar Health, Inc. (OSCR)

Oscar Health stock price has been in a strong uptrend in the past few weeks as the company shared plans on integrating artificial intelligence (AI) into its business. OSCR surged to a high of $24.2, its highest level since June 2021.

Oscar Health, an ACA marketplace pure play, is leading the way.

Oscar Health, Inc. (OSCR) reached $19.28 at the closing of the latest trading day, reflecting a +2.01% change compared to its last close.

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $18.93, marking a -1.05% move from the previous day.

While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don't build foundation models or design AI chips -- they apply existing AI technology to transform inefficient industries and outdated processes.

Oscar Health (OSCR) remains up 31% YTD as investors watch for developments on ACA enhanced subsidies, a key driver for its marketplace business. Policy risk looms with potential ACA subsidy expiration in 2026, but congressional pressure to extend could trigger a rally in OSCR shares. OSCR is leveraging ICHRA growth, AI-driven cost reductions, and improved customer experience to drive long-term margin expansion and membership gains.

MIAMI, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Long OSCR ETF (Ticker: OSCX).

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $18.5, marking a -2.48% move from the previous day.

Oscar Health Inc OSCR just became one of Wall Street's buzziest policy trades. With ACA (Affordable Care Act) subsidy chatter swirling ahead of a possible government shutdown, the tech-driven insurer is drawing Hims & Hers Health Inc HIMS style moonshot comparisons — and short sellers may be sitting on a powder keg.

Oscar Health is a volatile stock with high option premiums. A cash-secured put is one way to buy the stock for a discount.

Oscar Health stock is up 21% since my strong buy rating, outperforming the S&P 500's 4% return. Membership surpassed 2.0 million in June 2025, growing 28% year-over-year compared to just 13% ACA market growth. Expansion remains the primary catalyst, with coverage in 18 states and 446 counties, targeting 150 new metros by 2027.

Healthcare tech firm Oscar Health Inc. OSCR priced its offering of $355 million of 2.25% convertible senior subordinated notes due 2030 in a private offering.

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar”) (NYSE: OSCR) today announced the pricing of its offering of $355,000,000 aggregate principal amount of 2.25% convertible senior subordinated notes due 2030 (the “notes”) in a private offering (the “Offering”) to qualified investors.1 The offering size was increased from the previously announced offering size of $350,000,000 aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on September 18, 2025.

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $18.73, marking a -3.1% move from the previous day.

NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. (“Oscar”) (NYSE: OSCR) today announced its intention to offer, subject to market and other conditions, $350,000,000 aggregate principal amount of convertible senior subordinated notes due 2030 (the “notes”) in a private offering (the “Offering”) to qualified investors.1 Oscar also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first iss.

Oscar Health is poised for a strong rebound in 2026 after a challenging 2025, driven by significant premium rate increases and improved pricing discipline. The company's technology-driven platform and +Oscar business create a competitive edge, supporting both internal growth and external revenue streams. Despite industry headwinds and legislative uncertainty, Oscar's low valuation, strong revenue growth, and founder-led governance offer an attractive risk/reward profile.